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Background: Aleglitazar (ALE) is a balanced PPAR-α/γ agonist in Phase III for cardiovascular (CV) risk reduction following acute coronary 
syndrome in patients with type 2 diabetes (T2D). As well as evaluating renal effects of ALE in stage 3 chronic kidney disease patients with T2D, this 
Phase IIb study (AleNephro) assessed effects on CV risk factors.
methods: Patients with stage 3 chronic kidney disease and T2D were randomized to 52 weeks’ double-blind treatment with ALE 150 µg/d or 
pioglitazone (PIO) 45 mg/d, and 8 weeks’ follow-up. Secondary/tertiary endpoints included change from baseline in lipid parameters at 52 weeks, 
and safety and tolerability.
results: Superior improvements in lipids and similar reductions in high-sensitivity C-reactive protein (hs-CRP) were seen with ALE vs. PIO (Table). 
Changes from baseline in systolic and diastolic blood pressure (95% CI) were +1.7 ([[Unable to Display Character: &#8211;]]1.0, 4.5) and [[Unable 
to Display Character: &#8211;]]2.2 ([[Unable to Display Character: &#8211;]]3.9, [[Unable to Display Character: &#8211;]]0.5) mmHg for ALE 
and +2.3 ([[Unable to Display Character: &#8211;]]0.4, 5.1) and [[Unable to Display Character: &#8211;]]0.5 ([[Unable to Display Character: 
&#8211;]]2.3, 1.2) mmHg for PIO. Changes from baseline in body weight (95% CI) were +2.4 (1.6, 3.2) kg with ALE and +2.5 (1.7, 3.3) kg with PIO. 
No new toxicities were identified and the number of patients with adjudicated CV events was similar between groups.
conclusion: ALE had favorable effects on lipids compared with PIO, including a reduction in triglyceride:high-density lipoprotein cholesterol ratio. 
The effects of ALE on lipids and hs-CRP may indicate a reduction in CV risk, which is being evaluated in the Phase III AleCardio study. 
Parameter, % mean change at end of treatment 
(95% CI) (full analysis set)
ALE 150 µg (n = 149) PIO 45 mg (n = 148) Treatment difference (95% CI)
Triglycerides -33.6 (-41.1, -26.1) -14.1 (-21.7, -6.5) -19.5 (-27.3, -11.7) p < 0.001
HDL-C 22.0 (17.4, 26.6) 11.6 (6.9, 16.3) 10.4 (5.5, 15.2) p < 0.001
LDL-C* -7.3 (-13.2, -1.0) -0.3 (-6.8, 6.6) -7.0 (-13.2, -0.4) p = 0.039
Non-HDL-C -13.1 (-19.1, -7.0) -2.2 (-8.3, 4.0) -10.9 (-17.2, -4.6) p = 0.001
Total cholesterol -4.6 (-9.2, 0) 0.7 (-4.0, 5.4) -5.3 (-10.1, -0.5) p = 0.03
Triglyceride:HDL-C ratio -41.7 (-51.1, -32.4) -17.5 (-27.0, -8.0) -24.2 (-33.9, -14.5) p < 0.001
Total cholesterol:HDL-C ratio -19.8 (-24.7, -14.9) -6.6 (-11.5, -1.6) -13.2 (-18.3, -8.1) p < 0.001
ApoA1 6.4 (3.0, 9.8) -2.0 (-5.4, 1.4) 8.4 (4.9, 11.9) p < 0.001
ApoB -12.1 (-16.9, -7.2) -5.3 (-10.2, -0.3) -6.8 (-11.9, -1.7) p = 0.009
hs-CRP*† -20.2 (-37.0, 1.1) -27.8 (-43.0, -8.7) 7.6 (-10.4, 25.7) p = 0.42
* Log-transformed data. † Data from safety analysis population (ALE, n =149; PIO, n = 152).
ALE = aleglitazar, PIO = pioglitazone, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, Apo = 
apolipoprotein, hs-CRP = high-sensitivity C-reactive protein.
